ClinicalTrials.gg
CompletedNCT07400588GSBR-1290Updated Oct 21, 2026

Aleniglipron Phase 2 in Type 2 Diabetes Mellitus

A Phase 2 interventional study of Aleniglipron and Placebo in Obese, Obesity and Obesity Type 2 Diabetes Mellitus, sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics. Completed at 16 sites in United States. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics (part of Structure Therapeutics) · Phase 2, Interventional, and Treatment

Updated Oct 21, 2026Now CompletedEligibility revised+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
58
Allocation
Randomized
Ages
18 Years to 79 Years
Sex
All
01

Study summary

The purpose of this study is to assess the safety and tolerability of aleniglipron at doses up to 180 mg once daily (QD) in participants with T2DM who are living with obesity (body mass index [BMI] ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2).

02

Conditions studied

  • Obese
  • Obesity
  • Obesity Type 2 Diabetes Mellitus
  • Weight Loss

Keywords

  • Obese
  • obesity
  • Obesity Type 2 Diabetes
  • Weight Loss
03

In context

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's enrollment of 58 is below the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics is the lead sponsor of 10 studies on the registry; 3 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 21, 2026. See what changed

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed
  • A diagnosis of T2DM of ≥6 months,
  • On stable treatment for T2DM for at least 90 days prior to Screening
  • (HbA1c) ≥6.5% to ≤10% at Screening
  • Have a ≥27.0 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Are currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema. All participants must have a photo fundoscopy, optical coherence tomography, or slit lamp assessment prior to randomization and within the last 12 months to confirm the absence or stable status of diabetic retinopathy and/or macular edema.
  • Present or planned use of any drug that could interfere with glucose levels
  • Self-reported change in body weight >5 kg (11 pounds) within 3 months before screening
  • Have prior or planned surgical treatment for obesity (excluding liposuction or abdominoplasty, if performed >1 year prior to Screening)
  • Have or plan to have endoscopic and/or device-based therapy for obesity or have had device removal within the last 6 months prior to Screening, including, but not limited to, mucosal ablation, gastric artery embolization, intragastric balloon, and duodenal-jejunal endoluminal liner
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
58 participants (actual)

Study arms

  • Experimental
    Arm 1: Participants will receive aleniglipron administered orally

    Drug aleniglipron administered orally

    Drug: Aleniglipron

  • Experimental
    Arm 2: Participants will receive a placebo administered orally

    Drug placebo administered orally

    Drug: Placebo

Interventions

  • Drug aleniglipron administered orally

  • DrugPlacebo

    Drug placebo administered orally

06

What researchers measure

Primary outcomes

  1. Incidence, severity and relationship of AEs/SAEs

    Time frame: Baseline to week 31

  2. Assessment of vital signs

    Number of Participants with Clinically Significant Change from Baseline in Vital Signs: including Systolic and Diastolic Blood Pressure, Heart Rate, and temperature.

    Time frame: Baseline to week 31

  3. Assessment of laboratory measures

    Number of Participants with Abnormal Laboratory Parameters: including hematology, serum chemistry, coagulation

    Time frame: Baseline to week 31

  4. Assessment of Electrocardiograms (ECG)

    Number of Participants with Clinically Significant Change from Baseline in Electrocardiogram (ECG) Parameters: Common ECG-related variables will be assessed, including but not limited to: ventricular heart rate, PR interval, QRS duration, QT interval, and QTcF

    Time frame: Baseline to week 31

Secondary outcomes

  1. Absolute change in body weight from Baseline

    Time frame: Baseline to week 31

  2. Percent change in body weight from Baseline

    Time frame: Baseline to week 31

  3. Change in HbA1c from Baseline

    Time frame: Baseline to week 30

  4. Change in fasting plasma glucose from Baseline

    Time frame: Baseline to week 31

  5. PK parameters including but not limited to AUC

    Time frame: Baseline to week 30

  6. PK parameters including but not limited to Cmax

    Time frame: Baseline to week 30

  7. PK parameters including but not limited to Tmax

    Time frame: Baseline to week 30

  8. PK parameters including but not limited to Ctrough

    Time frame: Baseline to week 30

07

Study locations

16 sites
  • Research Site
    Anniston, Alabama 36207, United States
  • Research Site
    Lake Forest, California 92630, United States
  • Research Site
    Lomita, California 90717, United States
  • Research Site
    Hazelwood, Missouri 63042, United States
  • Research Site
    Columbus, Ohio 43212, United States
  • Research Site
    Moncks Corner, South Carolina 29461, United States
  • Research Site
    Chattanooga, Tennessee 37421, United States
  • Research Site
    Knoxville, Tennessee 37909, United States
  • Research Site
    Austin, Texas 78704, United States
  • Research Site
    DeSoto, Texas 75115, United States
  • Research Site
    Houston, Texas 77079, United States
  • Research Site
    Mesquite, Texas 75149, United States
  • Research Site
    San Antonio, Texas 78215, United States
  • Research Site
    San Antonio, Texas 78229, United States
  • Research Site
    San Antonio, Texas 78240, United States
  • Research Site
    Tomball, Texas 77375, United States
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address a specific research question in an approved data sharing request

Supporting information: Study protocol

Time frame: Data sharing requests will be considered beginning 36 months after the study publication (manuscript accepted for publication) and either 1) the product has been granted marketing authorization in at least two regulatory jurisdictions, or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Researchers will submit a request containing the research objectives, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). Gasherbrum Bio, Inc. does not grant external requests for individual de-identified patient data for the following purposes: Re-evaluating safety and efficacy end points already addressed in the product labelling, Assessing safety or efficacy for an indication in current development Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a panel of external advisors. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2025 to primary completion in Sep 2026, 9 months.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 9 months is below that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2025
First posted
Feb 10, 2026
StartActual
Dec 1, 2025
Primary completionActual
Sep 18, 2026
CompletionActual
Sep 18, 2026
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 21, 2026
Eligibility
1 inclusion criterion added
What changed in the criteria
Inclusion criteria
  • AddedOn stable treatment for T2DM for at least 90 days prior to Screening
Oct 21, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionAssessment of laboratory measures: how it is measured was reworded
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Active, not recruiting→Completed
    Eligibility 1 inclusion criterion added
    What changed in the criteria
    Inclusion criteria
    • AddedOn stable treatment for T2DM for at least 90 days prior to Screening
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionAssessment of laboratory measures: how it is measured was reworded
    + 3 other changes: verification date, date precision and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07400588
Responsible party
Sponsor
First posted
Feb 10, 2026
Start date
Dec 1, 2025
Primary completion
Sep 18, 2026
Completion
Sep 18, 2026
Last update
Oct 21, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aleniglipron

Start the discussion